Update on PT-141 / Bremelanotide
Hey guys,
Discovered this forum thread while searching around and very interested to read people's experiences with PT-141...
And I thought I'd contribute by posting the latest info about this drug's development, as it related to 'legalized' availability.
First off, PT-141 was renamed (likely for trademarking reasons) to 'Bremelanotide'. It had quite successful tests with both men and women in clinical trials, but was shot down by the FDA when Palatin Technologies applied for approval (for ED treatment) - the FDA citing concerns with increased blood pressure concerns.
Although interesting to note those cases were few and reportedly minor.. and LOW blood pressure side effects didn't stop their approval of Viagra etc.
Palatin then decided to begin developing a derivative(?) compound named PL-6983, which is very similar to Bremelanotide but arousal in animals tested happened at doses smaller than the dose where heightened blood pressure began. Note: both PL-6983 and Bremelanotide (initially) are administered via nasal spray.
However - since that announcement Palatin has stated they actually WILL continue developing Bremelanotide as a treatment for ED and FSAD, but administered via subcutaneous injection instead of by nasal spray.
AFAIK, PL-6983 is still in Phase 1 clinical trials (at best) right now, and not sure if Bremelanotide will have to restart at phase 1 or if they can reboot at phase 3 where their nasal spray tests ended off.
And that's the latest, as far as I'm aware.
Hope that was of interest to some!
~ "Jonny"